Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.
2.

Plasma ApoE elevations are associated with NAFLD: The PREVEND Study.

van den Berg EH, Corsetti JP, Bakker SJL, Dullaart RPF.

PLoS One. 2019 Aug 6;14(8):e0220659. doi: 10.1371/journal.pone.0220659. eCollection 2019.

3.

Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk.

Corsetti JP, Bakker SJL, Gansevoort RT, Gruppen EG, Connelly MA, Sparks CE, Dullaart RPF.

Int J Mol Sci. 2019 Feb 23;20(4). pii: E977. doi: 10.3390/ijms20040977.

4.

Insulin resistance involvement in prevalence of familial dysbetalipoproteinemia in ε2ε2 subjects by Bayesian network modeling.

Corsetti JP, Love TM, Sparks CE, Bakker SJL, Dullaart RPF.

Clin Biochem. 2018 Sep;59:31-36. doi: 10.1016/j.clinbiochem.2018.06.009. Epub 2018 Jun 18.

PMID:
29928902
5.

Roles of high apolipoprotein E blood levels and HDL in development of familial dysbetalipoproteinemia in ε2ε2 subjects.

Corsetti JP, Sparks CE, Bakker SJL, Gruppen EG, Dullaart RPF.

Clin Biochem. 2018 Feb;52:67-72. doi: 10.1016/j.clinbiochem.2017.11.010. Epub 2017 Nov 20.

PMID:
29157655
6.

Apolipoprotein E levels and apolipoprotein E genotypes in incident cardiovascular disease risk in subjects of the Prevention of Renal and Vascular End-stage disease study.

Corsetti JP, Gansevoort RT, Bakker SJL, Dullaart RPF.

J Clin Lipidol. 2016 Jul-Aug;10(4):842-850. doi: 10.1016/j.jacl.2016.03.003. Epub 2016 Mar 12.

PMID:
27578115
7.
8.

Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation.

Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE.

Atherosclerosis. 2016 Jul;250:1-8. doi: 10.1016/j.atherosclerosis.2016.04.017. Epub 2016 Apr 21.

PMID:
27174532
9.

Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Corsetti JP, Gansevoort RT, Bakker SJ, Sparks CE, Vart P, Dullaart RP.

J Am Soc Nephrol. 2014 Dec;25(12):2906-15. doi: 10.1681/ASN.2013121256. Epub 2014 May 22.

10.

High-density lipoproteins: taking the good with the bad.

Sparks CE, Corsetti JP, Sparks JD.

Curr Opin Lipidol. 2014 Jun;25(3):230-2. doi: 10.1097/MOL.0000000000000079. No abstract available.

PMID:
24763089
11.

Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.

Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE.

PLoS One. 2013 Jul 9;8(7):e68920. doi: 10.1371/journal.pone.0068920. Print 2013.

12.

Reactive Oxygen Species, SUMOylation, and Endothelial Inflammation.

Le NT, Corsetti JP, Dehoff-Sparks JL, Sparks CE, Fujiwara K, Abe J.

Int J Inflam. 2012;2012:678190. Epub 2012 Sep 6.

13.

Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein.

Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP.

PLoS One. 2012;7(6):e39110. doi: 10.1371/journal.pone.0039110. Epub 2012 Jun 18.

14.

Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein.

Corsetti JP, Gansevoort RT, Bakker SJ, Navis G, Sparks CE, Dullaart RP.

Metabolism. 2012 Jul;61(7):996-1002. doi: 10.1016/j.metabol.2011.11.010. Epub 2012 Jan 5.

15.

Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels.

Corsetti JP, Ryan D, Moss AJ, McCarthy J, Goldenberg I, Zareba W, Sparks CE.

Thromb Haemost. 2011 Dec;106(6):1170-8. doi: 10.1160/TH11-03-0206. Epub 2011 Oct 20.

PMID:
22011848
16.

Glycerol as a reference material for fecal fat quantitation using low-resolution time domain ¹H NMR spectroscopy.

Corsetti JP, Sterry J, Sakpal M, Lefevre BH, Ryan D.

Clin Biochem. 2011 Nov;44(16):1352-4. doi: 10.1016/j.clinbiochem.2011.08.1128. Epub 2011 Aug 26.

PMID:
21889932
17.

An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients.

Refaai MA, Fialkow LB, Heal JM, Henrichs KF, Spinelli SL, Phipps RP, Masel E, Smith BH, Corsetti JP, Francis CW, Bankey PE, Blumberg N.

Vox Sang. 2011 Jul;101(1):55-60. doi: 10.1111/j.1423-0410.2010.01464.x. Epub 2011 Mar 18.

18.

LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP.

Corsetti JP, Gansevoort RT, Navis G, Sparks CE, Dullaart RP.

Atherosclerosis. 2011 Feb;214(2):373-6. doi: 10.1016/j.atherosclerosis.2010.11.029. Epub 2010 Nov 26.

19.

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.

Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Sparks CE.

Arterioscler Thromb Vasc Biol. 2010 Aug;30(8):1657-64. doi: 10.1161/ATVBAHA.110.207977. Epub 2010 May 20.

20.

PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry.

Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, Sofat R, Nicolaides AN, Corsetti JP, Fowkes FG, Tzoulaki I, Kumari M, Brunner EJ, Kivimaki M, Marmot MG, Hoffmann MM, Winkler K, März W, Ye S, Stirnadel HA, Boekholdt SM, Khaw KT, Humphries SE, Sandhu MS, Hingorani AD, Talmud PJ.

Circulation. 2010 Jun 1;121(21):2284-93. doi: 10.1161/CIRCULATIONAHA.109.923383. Epub 2010 May 17. Erratum in: Circulation. 2010 Jul 20;122(3):e400. Boekholdt, S Matthijs [added].

Supplemental Content

Loading ...
Support Center